Skip to main content

Table 1 Summary of subgroup characteristics in 1662 patients

From: Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients

Variables (%)

Triple negative

ERBB2+

HR+/ERBB2-

Pvalue

 

n = 321

n = 444

n = 897

 

Mean age at diagnosis (year, ± SD)

52.02 ± 10.49

52.12 ± 9.99

53.16 ± 11.56

0.416

Tumor size

    

   ≤ 2 cm

139 (43.30)

148 (33.33)

439 (48.94)

< 0.001

   >2 cm

182 (56.70)

296 (66.67)

458 (51.06)

 

Number of ALNs involved

    

   0

190 (59.19)

233 (52.48)

538 (59.98)

 

   1-3

72 (22.43)

107 (24.10)

214 (23.86)

0.020

   ≥ 4

59 (18.38)

104 (23.42)

145 (16.16)

 

Histological grade

    

   I/II

151(61.56)

237 (74.29)

499 (81.80)

0.002

   III

60 (28.44)

82 (25.71)

111 (18.20)

 

   Not known

110

126

287

 

Systemic treatment

    

   Yes

302 (94.08)

426 (95.95)

852 (94.98)

0.494

   No

19 (5.92)

18 (4.05)

45 (5.02)

 

All relapse

    

   Yes

51 (15.79)

65 (14.64)

79 (8.81)

< 0.001

   No

270 (84.11)

379 (85.36)

818 (91.19)

 

Locoregional relapse

    

   Yes

25 (7.79)

35 (7.79)

35 (3.90)

0.003

   No

296 (92.21)

409 (92.12)

862 (96.10)

 

   Mean TTE (years)

2.19

2.03

2.02

------

Visceral relapse

    

   Yes

15 (4.67)

25 (5.63)

23 (2.56)

0.014

   No

306 (95.33)

419 (94.37)

874 (97.44)

 

   Mean TTE (years)

1.64

2.02

2.49

------

Bone relapse

    

   Yes

12 (3.74)

7 (1.58)

16 (1.78)

0.074

   No

309 (96.26)

437 (98.42)

881 (98.22)

 

   Mean TTE (years)

3.04

2.24

2.57

------

  1. Abbreviations: HR = hormone receptor; SD = standard deviation; ALNs = axillary lymph nodes; TTE = time to event